Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 19;5:918.
doi: 10.12688/f1000research.8729.3. eCollection 2016.

Hypnotic Drug Risks of Mortality, Infection, Depression, and Cancer: But Lack of Benefit

Affiliations
Free PMC article
Review

Hypnotic Drug Risks of Mortality, Infection, Depression, and Cancer: But Lack of Benefit

Daniel F Kripke. F1000Res. .
Free PMC article

Abstract

This is a review of hypnotic drug risks and benefits. Almost every month, new information appears about the risks of hypnotics (sleeping pills). The most important risks of hypnotics include excess mortality (especially overdose deaths, quiet deaths at night, and suicides), infections, cancer, depression, automobile crashes, falls, other accidents, and hypnotic-withdrawal insomnia. Short-term use of one-two prescriptions is associated with even greater risk per dose than long-term use. Hypnotics have usually been prescribed without approved indication, most often with specific contraindications, but even when indicated, there is little or no benefit. The recommended doses objectively increase sleep little if at all, daytime performance is often made worse (not better) and the lack of general health benefits is commonly misrepresented in advertising. Treatments such as the cognitive behavioral treatment of insomnia and bright light treatment of circadian rhythm disorders offer safer and more effective alternative approaches to insomnia.

Keywords: cancer; depression; hypnotics and sedatives; infection; insomnia; mortality; sleep.

Conflict of interest statement

Competing interests: Since 1979 publication of hypnotics’ epidemiology from the American Cancer Society CPSI study, the author has been a frequent critic of hypnotics risks and benefits, especially through his non-profit internet web site, http://www.DarkSideOfSleepingPills.com, that offers readers additional information and references about hypnotics. Dr. Kripke's family owns non-controlling stock in a large conglomerate that in turn invested a tiny percentage of its capital in Sanofi-Aventis and other manufacturers of hypnotics. The author has advised the USA Food and Drug Administration to take certain actions regarding hypnotics (Petition available at http://www.regulations.gov/#!docketDetail;D=FDA-2015-P-3959). Litigation to mitigate the leading hypnotic generics manufacturer and a leading California pharmacy provider has been commenced. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, other stock ownership or options, expert testimony, grants or patents received or pending or royalties. No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by 15 articles

See all "Cited by" articles

References

    1. Rudd RA, Aleshire N, Zibbell JE, et al. : Increases in Drug and Opioid Overdose Deaths--United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82. 10.15585/mmwr.mm6450a3 - DOI - PubMed
    1. Ahman FB, Rossen LM, Spencer MR, et al. : Provisional drug overdose death counts.National Center for Health Statistics. Vital Statistics Rapid Release. 2018. Reference Source
    1. Rockett IR, Lilly CL, Jia H, et al. : Self-injury Mortality in the United States in the Early 21st Century: A Comparison With Proximally Ranked Diseases. JAMA Psychiatry. 2016;73(10):1072–81. 10.1001/jamapsychiatry.2016.1870 - DOI - PMC - PubMed
    1. Ford ES, Wheaton AG, Cunningham TJ, et al. : Trends in Outpatient Visits for Insomnia, Sleep Apnea, and Prescriptions for Sleep Medications among US Adults: Findings from the National Ambulatory Medical Care Survey 1999–2010. Sleep. 2014;37(8):1283–93. 10.5665/sleep.3914 - DOI - PMC - PubMed
    1. Crow D: Ambien defence: the real side effects of sleeping pills. Financial Times Sect. US.2018. Reference Source

Grant support

The author(s) declared that no grants were involved in supporting this work.

LinkOut - more resources

Feedback